Sign inJoin waitlistJoin the waitlist

EB

Erin Barr

Associate Professor · Texas Tech University Health Sciences Center at Lubbock

Credentials: · · ·

History

Texas Tech University Health Sciences Center at Lubbock
Present

Pediatrics
2012–2015
Doctor of Medicine
2008–2012

Research

Genetic Predisposition to Neuroblastoma
Review · Children · 2018 · First of 2 authors · 67 citations
5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with Neuroblastoma
Clinical Cancer Research · 2020 · Co-first of 18 authors · 33 citations
5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype
JCO Precision Oncology · 2019 · 25 citations

Mark Applebaum
4 papers
Susan Cohn
4 papers
Chuan He
2 papers
Lucy Godley
2 papers
Ami Desai
1 paper
Amy Armstrong
1 paper · 1 as a fellow
Clare Twist
1 paper
EA
Elijah Adkins
1 paper
Elizabeth Sokol
1 paper
John Maris
1 paper
Julie Park
1 paper
Katherine Matthay
1 paper

Clinical trials

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma
Principal investigator · Active not recruiting · Phase 1
Children's Oncology Group
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2029